FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2563316179> ?p ?o ?g. }

• W2563316179 abstract "Abstract Abstract 1494 Introduction: Burkitt lymphoma (BL) and B-cell acute lymphoblastic leukemia (B-ALL) are very aggressive malignancies with poor prognosis unless treated with highly specific intensive programs. The German Multicenter Study Group for Adult ALL piloted a short intensive rituximab (R)-chemotherapy program that improved outcome compared to the prior regimen (Hoelzer et al, Blood 110:abstr 518, 2007). The Northern Italy Leukemia Group adopted the same protocol to treat 105 consecutive, unselected adult patients with BL and B-ALL. Aim: To assess long-term outcome and toxicity according to pre-therapy risk factors predominantly identified by higher age and/or performance status (PS) according to the Eastern Cooperative Oncology Group score. Patients and Methods: Between December 2002 and June 2010, 55 BL (stage III-IV 53%, bulky 45%, extranodal involvement 64%) and 50 B-ALL patients were treated. Median age was 47 years (range 17–78), 31% were >55 years, 15% had a PS >2, and 15% were HIV+. Treatment consisted of 6 R-chemotherapy courses (4 in stage I-II disease without mediastinal/extranodal involvement), two additional R doses at completion of chemotherapy and local radiotherapy in case of mediastinal/CNS disease or residual tumor. R-chemotherapy blocks were as follows: A) prednisone-cyclophosphamide prephase (course 1 only), R plus dexamethasone, vincristine, ifosphamide, HD-methotrexate, teniposide [or etoposide], Ara-C, intrathecal therapy [IT]; B) R plus dexamethasone, vincristine, cyclophosphamide, HD-methotrexate, adriamycin, IT; C) R plus dexamethasone, vindesine, HD-methotrexate, etoposide, HD-Ara-C. The A-C sequence was repeated once. Patients aged >55 years received only courses A and B with methotrexate 0.5 g/m2. Results: Eighty-three total patients (79%) achieved CR, 8 were refractory and 14 died of complications. All early deaths occurred in patients older than 40 years, correlated with stage III-IV BL or B-ALL (n=13), PS ≥1 (n=10), and were mainly caused by infections. Among CR patients, 67 (81%) received all planned therapy and 16 did not (toxicity/CR death 11, early relapse 3, other 2). The mean intercycle time (MIT) between chemotherapy courses was 29 days (range 22–52). After a median follow-up of 23.8 months (range 0.7–99), 65 patients (61%) were alive in 1st CR, 19 (18%) died of complications (7 in CR, including 2 late deaths due to secondary AML and cardiovascular accident), and 19 had refractory or recurrent disease. Ten of 67 patients treated with MIT >25 days relapsed within 6 months (15%), compared to one of 15 treated with MIT ≤25 days (7%, P=.34). Projected 3-year overall and disease-free survival and were 67% (OS) and 75% (DFS), respectively. In univariate analysis age, normal LDH, ECOG PS <2 and lack of CNS involvement were favorable prognostic factors, whereas MIT was of borderline significance. In multivariate analysis, age and PS were highly predictive for OS and DFS. In a cumulative analysis, patients aged >55 years with PS ≥1 had the worst outcome (n=24; OS 28% and DFS 36%), those with PS=0 fared as well as patients aged ≤55 years with PS=0–1 (n=55; OS 89% and DFS 89%) and the younger patients with PS >1 represented an intermediate-good risk category (n=26; OS 61% and DFS 77%) (P=.0000). The incidence of TRM and relapse varied significantly among the 3 groups, each contributing almost equally to the final outcome. Conclusion: The excellent therapeutic potential of this treatment (89% cure rate) was confirmed in patients with PS=0, regardless of age, and in younger patients with PS=0–1, whereas the results were still good, though significantly inferior, with PS >1 (61% cure rate). Prompt diagnosis and referral of BL and B-ALL patients is essential for exploiting the prognostic advantage associated with a better PS, together with maximized anti-infectious measures and rapid re-cycling of chemo-immunotherapy blocks. Disclosures: No relevant conflicts of interest to declare." @default.
• W2563316179 created "2017-01-06" @default.
• W2563316179 creator A5004011545 @default.
• W2563316179 creator A5004450449 @default.
• W2563316179 creator A5005558035 @default.
• W2563316179 creator A5008839925 @default.
• W2563316179 creator A5020522150 @default.
• W2563316179 creator A5029235354 @default.
• W2563316179 creator A5032523598 @default.
• W2563316179 creator A5041794776 @default.
• W2563316179 creator A5042199709 @default.
• W2563316179 creator A5050369634 @default.
• W2563316179 creator A5054926155 @default.
• W2563316179 creator A5055401685 @default.
• W2563316179 creator A5064975574 @default.
• W2563316179 creator A5066213019 @default.
• W2563316179 creator A5067318724 @default.
• W2563316179 creator A5069596141 @default.
• W2563316179 creator A5070777479 @default.
• W2563316179 creator A5071784692 @default.
• W2563316179 creator A5078492047 @default.
• W2563316179 creator A5079098188 @default.
• W2563316179 date "2012-11-16" @default.
• W2563316179 modified "2023-10-01" @default.
• W2563316179 title "High Cure Rates in Burkitt Leukemia and Lymphoma: NILG Study of the German Short Intensive Rituximab-Chemotherapy Program" @default.
• W2563316179 doi "https://doi.org/10.1182/blood.v120.21.1494.1494" @default.
• W2563316179 hasPublicationYear "2012" @default.
• W2563316179 type Work @default.
• W2563316179 sameAs 2563316179 @default.
• W2563316179 citedByCount "1" @default.
• W2563316179 countsByYear W25633161792013 @default.
• W2563316179 crossrefType "journal-article" @default.
• W2563316179 hasAuthorship W2563316179A5004011545 @default.
• W2563316179 hasAuthorship W2563316179A5004450449 @default.
• W2563316179 hasAuthorship W2563316179A5005558035 @default.
• W2563316179 hasAuthorship W2563316179A5008839925 @default.
• W2563316179 hasAuthorship W2563316179A5020522150 @default.
• W2563316179 hasAuthorship W2563316179A5029235354 @default.
• W2563316179 hasAuthorship W2563316179A5032523598 @default.
• W2563316179 hasAuthorship W2563316179A5041794776 @default.
• W2563316179 hasAuthorship W2563316179A5042199709 @default.
• W2563316179 hasAuthorship W2563316179A5050369634 @default.
• W2563316179 hasAuthorship W2563316179A5054926155 @default.
• W2563316179 hasAuthorship W2563316179A5055401685 @default.
• W2563316179 hasAuthorship W2563316179A5064975574 @default.
• W2563316179 hasAuthorship W2563316179A5066213019 @default.
• W2563316179 hasAuthorship W2563316179A5067318724 @default.
• W2563316179 hasAuthorship W2563316179A5069596141 @default.
• W2563316179 hasAuthorship W2563316179A5070777479 @default.
• W2563316179 hasAuthorship W2563316179A5071784692 @default.
• W2563316179 hasAuthorship W2563316179A5078492047 @default.
• W2563316179 hasAuthorship W2563316179A5079098188 @default.
• W2563316179 hasConcept C126322002 @default.
• W2563316179 hasConcept C141071460 @default.
• W2563316179 hasConcept C143998085 @default.
• W2563316179 hasConcept C2776694085 @default.
• W2563316179 hasConcept C2776755627 @default.
• W2563316179 hasConcept C2778119113 @default.
• W2563316179 hasConcept C2778336483 @default.
• W2563316179 hasConcept C2779321808 @default.
• W2563316179 hasConcept C2779338263 @default.
• W2563316179 hasConcept C2779429289 @default.
• W2563316179 hasConcept C2780653079 @default.
• W2563316179 hasConcept C2781413609 @default.
• W2563316179 hasConcept C71924100 @default.
• W2563316179 hasConcept C90924648 @default.
• W2563316179 hasConceptScore W2563316179C126322002 @default.
• W2563316179 hasConceptScore W2563316179C141071460 @default.
• W2563316179 hasConceptScore W2563316179C143998085 @default.
• W2563316179 hasConceptScore W2563316179C2776694085 @default.
• W2563316179 hasConceptScore W2563316179C2776755627 @default.
• W2563316179 hasConceptScore W2563316179C2778119113 @default.
• W2563316179 hasConceptScore W2563316179C2778336483 @default.
• W2563316179 hasConceptScore W2563316179C2779321808 @default.
• W2563316179 hasConceptScore W2563316179C2779338263 @default.
• W2563316179 hasConceptScore W2563316179C2779429289 @default.
• W2563316179 hasConceptScore W2563316179C2780653079 @default.
• W2563316179 hasConceptScore W2563316179C2781413609 @default.
• W2563316179 hasConceptScore W2563316179C71924100 @default.
• W2563316179 hasConceptScore W2563316179C90924648 @default.
• W2563316179 hasLocation W25633161791 @default.
• W2563316179 hasOpenAccess W2563316179 @default.
• W2563316179 hasPrimaryLocation W25633161791 @default.
• W2563316179 hasRelatedWork W1864995945 @default.
• W2563316179 hasRelatedWork W1930245694 @default.
• W2563316179 hasRelatedWork W2079546047 @default.
• W2563316179 hasRelatedWork W2095394060 @default.
• W2563316179 hasRelatedWork W2183352065 @default.
• W2563316179 hasRelatedWork W2307541432 @default.
• W2563316179 hasRelatedWork W2402114871 @default.
• W2563316179 hasRelatedWork W2403128117 @default.
• W2563316179 hasRelatedWork W24057889 @default.
• W2563316179 hasRelatedWork W2547967099 @default.
• W2563316179 hasRelatedWork W2550172655 @default.
• W2563316179 hasRelatedWork W2557062468 @default.
• W2563316179 hasRelatedWork W2560406235 @default.
• W2563316179 hasRelatedWork W2564404529 @default.
• W2563316179 hasRelatedWork W2575906056 @default.
• W2563316179 hasRelatedWork W2582455958 @default.
• W2563316179 hasRelatedWork W2586089700 @default.

• next